文献速递乳腺MR

乳腺癌患者新辅助化疗反应预测的DCE-MRI影像组学分析

Radiomic analysis of DCE-MRI for prediction of response to neoadjuvant chemotherapy in breast cancer patients.
PubMed 文献 · Eur J Radiol · 2017-06-28

研究利用57例乳腺癌患者新辅助化疗前的DCE-MRI图像提取158个影像组学特征,以RECIST标准分为47例反应者和10例无反应者,采用进化算法筛选特征并结合留一交叉验证构建分类器,主队列AUC为0.910,独立验证队列(46例)AUC为0.874,但跨队列验证AUC为0.713和0.683,两队列平均ROC曲线AUC为0.703。

要点

  • 新辅助化疗前DCE-MRI影像组学特征与乳腺癌化疗反应相关。
  • 主队列留一交叉验证AUC为0.910,独立验证队列AUC为0.874。
  • 特征跨队列验证时AUC降至0.713和0.683,平均AUC为0.703。

核心结论

  • 治疗前乳腺DCE-MRI影像组学特征的定量分析可作为与肿瘤新辅助化疗反应相关的有价值影像标志物。

研究设计与样本

  • 研究论文;主队列57例乳腺癌患者新辅助化疗前DCE-MRI图像,按RECIST标准分为47例反应者和10例无反应者;额外独立验证数据集46例;分割乳腺区域计算158个影像组学特征,采用基于进化算法的Wrapper子集评估器筛选最优特征,以留一交叉验证训练和测试分类器。

诊断标准与关键数值

  • 主队列经进化算法筛选出12个最优影像特征用于分类,独立验证数据集按相同流程产生11个特征、其中7个与主队列相同;主队列留一交叉验证AUC为0.910,可重复性研究队列AUC为0.874,用主队列最优特征测试可重复性队列AUC为0.713,用可重复性队列特征测试主队列AUC为0.683,两队列平均ROC曲线AUC为0.703。

局限性

  • 用主队列最优特征测试可重复性队列时AUC为0.713,用可重复性队列特征测试主队列时AUC为0.683,跨队列验证性能低于各自队列内交叉验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: To enhance the accurate prediction of the response to neoadjuvant chemotherapy (NAC) in breast cancer patients by using a quantitative analysis of dynamic enhancement magnetic resonance imaging (DCE-MRI).

MATERIALS AND METHODS: A dataset of 57 cancer patients with breast DCE-MR images acquired before NAC was used. Among them, 47 patients were Responders, and 10 patients were non-Responders based on the RECIST criteria. The breast regions were segmented on the MR images, and a total of 158 radiomic features were computed to represent the morphologic, dynamic, and the texture of the tumors as well as the background parenchymal features. The optimal subset of features was selected using evolutionary based Wrapper Subset Evaluator. The classifier was trained and tested using a leave-one-out cross-validation (LOOCV) method to classify Responder and non-Responder cases. The area under a receiver operating characteristic curve (AUC) was computed to assess the classifier performance. An additional independent dataset with 46 patients was also included to validate the results.

RESULTS: The evolutionary algorithm (EA)-based method identified optimal subsets comprising 12 image features that were fit for classification for the main cohort. Following the same feature selection procedure, the independent validation dataset produced 11 image features, 7 of which were identical to those from the main cohort. The classifier based on the features yield a LOOCV AUC of 0.910 and 0.874 for the main and the reproducibility study cohort, respectively. If the optimal features in the main cohort were utilized to test performance on the reproducibility cohort, the classifier generated an AUC of 0.713. While the features developed in the reproducibility cohort were applied to test the main cohort, the classifier achieved an AUC of 0.683. The AUC of the averaged receiver operating characteristic (ROC) curve for the two data cohort was 0.703.

CONCLUSIONS: This study demonstrated that quantitative analyses of radiomic features from pretreatment breast DCE-MRI data could be used as valuable image markers that are associated with tumor response to NAC.

来源:Eur J Radiol,查看原文。版权归原作者所有。

引用

  1. Fan M, Wu G, Cheng H, et al. Radiomic analysis of DCE-MRI for prediction of response to neoadjuvant chemotherapy in breast cancer patients. Eur J Radiol. 2017. PMID: 28712700. doi:10.1016/j.ejrad.2017.06.019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。